Literature DB >> 28577855

Quantitative analyses reveal distinct sensitivities of the capture of HIV-1 primary viruses and pseudoviruses to broadly neutralizing antibodies.

Jiae Kim1, Ousman Jobe1, Kristina K Peachman1, Nelson L Michael2, Merlin L Robb3, Mangala Rao4, Venigalla B Rao5.   

Abstract

Development of vaccines capable of eliciting broadly neutralizing antibodies (bNAbs) is a key goal to controlling the global AIDS epidemic. To be effective, bNAbs must block the capture of HIV-1 to prevent viral acquisition and establishment of reservoirs. However, the role of bNAbs, particularly during initial exposure of primary viruses to host cells, has not been fully examined. Using a sensitive, quantitative, and high-throughput qRT-PCR assay, we found that primary viruses were captured by host cells and converted into a trypsin-resistant form in less than five minutes. We discovered, unexpectedly, that bNAbs did not block primary virus capture, although they inhibited the capture of pseudoviruses/IMCs and production of progeny viruses at 48h. Further, viruses escaped bNAb inhibition unless the bNAbs were present in the initial minutes of exposure of virus to host cells. These findings will have important implications for HIV-1 vaccine design and determination of vaccine efficacy.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  A3R5.7 cells; Broadly neutralizing antibodies; HIV-1 transmission; HIV-1 vaccine; Viral capture; Virus entry; qRT‐PCR

Mesh:

Substances:

Year:  2017        PMID: 28577855      PMCID: PMC5531191          DOI: 10.1016/j.virol.2017.05.015

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  43 in total

1.  DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells.

Authors:  T B Geijtenbeek; D S Kwon; R Torensma; S J van Vliet; G C van Duijnhoven; J Middel; I L Cornelissen; H S Nottet; V N KewalRamani; D R Littman; C G Figdor; Y van Kooyk
Journal:  Cell       Date:  2000-03-03       Impact factor: 41.582

2.  Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.

Authors:  Cynthia A Derdeyn; Julie M Decker; Frederic Bibollet-Ruche; John L Mokili; Mark Muldoon; Scott A Denham; Marintha L Heil; Francis Kasolo; Rosemary Musonda; Beatrice H Hahn; George M Shaw; Bette T Korber; Susan Allen; Eric Hunter
Journal:  Science       Date:  2004-03-26       Impact factor: 47.728

3.  Distribution and three-dimensional structure of AIDS virus envelope spikes.

Authors:  Ping Zhu; Jun Liu; Julian Bess; Elena Chertova; Jeffrey D Lifson; Henry Grisé; Gilad A Ofek; Kenneth A Taylor; Kenneth H Roux
Journal:  Nature       Date:  2006-05-24       Impact factor: 49.962

4.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

5.  Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.

Authors:  Elena Chertova; Julian W Bess; Bruce J Crise; Raymond C Sowder II; Terra M Schaden; Joanne M Hilburn; James A Hoxie; Raoul E Benveniste; Jeffrey D Lifson; Louis E Henderson; Larry O Arthur
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  Potential role for CD63 in CCR5-mediated human immunodeficiency virus type 1 infection of macrophages.

Authors:  Jana J von Lindern; Daniel Rojo; Kathie Grovit-Ferbas; Christine Yeramian; Cheng Deng; Georges Herbein; Monique R Ferguson; Todd C Pappas; Julie M Decker; Anjali Singh; Ronald G Collman; William A O'Brien
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

7.  Selection of HIV variants with signature genotypic characteristics during heterosexual transmission.

Authors:  Manish Sagar; Oliver Laeyendecker; Sandra Lee; Jordyn Gamiel; Maria J Wawer; Ronald H Gray; David Serwadda; Nelson K Sewankambo; James C Shepherd; Jonathan Toma; Wei Huang; Thomas C Quinn
Journal:  J Infect Dis       Date:  2009-02-15       Impact factor: 5.226

8.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Authors:  Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim
Journal:  N Engl J Med       Date:  2009-10-20       Impact factor: 91.245

9.  Functionally distinct transmission of human immunodeficiency virus type 1 mediated by immature and mature dendritic cells.

Authors:  Jian-Hua Wang; Alicia M Janas; Wendy J Olson; Li Wu
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

10.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

View more
  4 in total

1.  Human Primary Macrophages Derived In Vitro from Circulating Monocytes Comprise Adherent and Non-Adherent Subsets with Differential Expression of Siglec-1 and CD4 and Permissiveness to HIV-1 Infection.

Authors:  Ousman Jobe; Jiae Kim; Eric Tycksen; Sayali Onkar; Nelson L Michael; Carl R Alving; Mangala Rao
Journal:  Front Immunol       Date:  2017-10-23       Impact factor: 7.561

2.  Tracking Human Immunodeficiency Virus-1 Infection in the Humanized DRAG Mouse Model.

Authors:  Jiae Kim; Kristina K Peachman; Ousman Jobe; Elaine B Morrison; Atef Allam; Linda Jagodzinski; Sofia A Casares; Mangala Rao
Journal:  Front Immunol       Date:  2017-10-27       Impact factor: 7.561

3.  Primary HIV-1 and Infectious Molecular Clones Are Differentially Susceptible to Broadly Neutralizing Antibodies.

Authors:  Jiae Kim; Venigalla B Rao; Mangala Rao
Journal:  Vaccines (Basel)       Date:  2020-12-21

4.  Army liposome formulation containing QS-21 render human monocyte-derived macrophages less permissive to HIV-1 infection by upregulating ABOBEC3A.

Authors:  Ousman Jobe; Jiae Kim; Daniel O Pinto; Zuzana Villar; Tiffany Hewitt; Elizabeth H Duncan; Alexander Anderson; Neelakshi Gohain; Hua Gong; Courtney Tucker; Carl R Alving; Gary R Matyas; Elke Bergmann-Leitner; Mangala Rao
Journal:  Sci Rep       Date:  2022-05-09       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.